Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Gynecologic 3Head & Neck 2Breast 2Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 16Uterine Cervical Neoplasms 8Melanoma 7Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Breast Neoplasms 5Recurrence 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 27Cyclophosphamide 14Gemcitabine 13fludarabine 11Carboplatin 10aldesleukin 9Trastuzumab 9Specimen Handling 9Nivolumab 9Magnetic Resonance Spectroscopy 8Biopsy 8olaparib 7Cisplatin 7Paclitaxel 6palbociclib 5atezolizumab 5Taxes 5Early Intervention, Educational 5Oxaliplatin 4Methods 4Irinotecan 4Drug Therapy 4Docetaxel 4Cetuximab 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4talazoparib 3spartalizumab 3pertuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Interleukin-2 × Gynecologic × Clear all
NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Alaunos Therapeutics

Phase 1/2 Terminated
8 enrolled 12 charts
GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡